Consumer-Facing Businesses Food - Personal Care - OTC - Healthcare United States

Innovation | Value Creation | Top-Bottom Line Growth | Operation Efficiencies | Transformation | Strategic Growth Partners I High Performing Organizations

Accomplished leader drives results for corporate divisions ($200MM to $2BB). Exceeds target goals with focused and differentiated strategy, consumer insight-driven growth plans, operational excellence and building accountable, empowered organizations.


Relentless focus on articulating and driving clear strategic advantages within the organization: brand value proposition, customer value, cost structure. Connects with consumers/customers to understand their needs, then uses this insight to continually strengthen business strategy. The result is acceleration of top and bottom line growth, category leadership and market share.


Works across the entire value chain to quickly assess and prioritize where resources must be refocused and process improvements must be made to improve operating margins and lower capital investment needs. Applies Six Sigma principles to eliminate redundancies and potential points of confusion so that the business and brands can remain proactive in creating value and maintaining their category leadership positions.


Reaches beyond “business as usual” to create products and brand value positions that standout in the market and resonate with consumers. Continually leverages consumer insights to ensure disciplined innovation so that brands stay relevant and meaningful with consumer needs.


Advocates continuous professional development of people within organizations to create a break-through culture. This results in highly engaged work teams where ownership and risk-taking are encouraged; streamlined organization structures and decision processes. As a result the organization is more nimble and can quickly meet the changing needs of today’s dynamic and multi-cultural consumer market.

Ms Bridgette Heller

Coolaborator Canada

Miss Zoe ZHANG
BD Director 

Covalent Development United States

Covalent Development facilite le développement de votre portefeuille clients et de votre chiffre d'affaires en Amérique du Nord. Nous sommes spécialisés dans la vente de services complexes et innovants à l'Industrie Pharmaceutique et Cosmétique.

Based in Central New Jersey, Covalent Development offers to develop US business activities of Biotech companies.  
The state of New Jersey is home to more than 300 biotechnology companies and 20 pharmaceutical and medical technology firms (17 out of the world’s top 20 have major facilities in the state). This incredible concentration offers extraordinary opportunities to develop your business.  
New York, Boston, Washington DC, North Carolina and Philadelphia are close and there is only 3 hours of time difference with West Coast. It makes things easier to reach your prospects and clients!


Basée dans le centre du New Jersey, Covalent Development propose de développer vos activités aux Etats-Unis. 
L'état du New Jersey héberge plus de 300 entreprises de biotechnologie ainsi que 20 sociétés pharmaceutiques et médicales (17 du top 20 sont implantées dans l'état). C'est une localisation idéale pour développer votre business. 
New York, Boston, Washington DC, la Caroline du Nord et Philadelphia sont proches et il n'y a que 3 heures de décalage horaire avec la côte ouest. De quoi faciliter les échanges avec vos prospects et clients ! 

Ms Delphine Davan-Gatti
Ms Delphine Davan-Gatti
Owner, Founder 
Mr Anselmo Rivera
Head of Business Development 

CreaPharm group France

CREAPHARM GROUP Providing customized international clinical supplies solutions to meet your needs & Improving your patients

CreaPharm group is a customer-focused team of 164 people applying their expertise and innovative solutions to offer a first-class service to their 250 active customers.

We are a mid-size subcontractor that is big enough to offer high range of services of the highest quality while at the same time being small enough to offer dedicated care and to adapt its processes according to the specificities of each client request.

Our 4 facilities are fully compliant with Good Manufacturing Practices and Good Distribution Practices and are inspected by the French medicines agency ANSM for human medicinal products and the ANSES for veterinary products.

Our team has years of experience in managing all types of projects with agility, flexibility and responsiveness.

Clinical Supplies:

·         GMP manufacturing,

·         Packaging and labelling,

·         International distribution,

·         Comparator and ancillary goods sourcing,

·         IMP importation and QP release services,

·         Biological sampling kit production


Pharmaceutical Contract Manufacturing:

·         Packaging design and development, Packaging of market drugs,

·         Special packing and repacking activities,

·         Late stage customization


Cosmetic Contract Manufacturing:

·         Formulation of cosmetic products,

·         A wide range of formulas available,

·         Packaging design and development, Manufacturing & packaging of cosmetic products

Mrs Carla DA COSTA
Business Development Director 

CUNY United States

CUNY is home to more than 100 research centers, institutes and consortia, which provide research opportunities for faculty and students, employment, internships, and special events. These centers focus their efforts on a wide range of areas, including aging, applied sciences, corporate integrity, transportation systems, ethnic studies, performing arts, sustainable energy and urban studies, to name a few.

Many institutions reflect CUNY’s support of state-of-the-art education and research, such as the Institute for Ultrafast Spectroscopy and Lasers. Others exemplify the University’s commitment to service and historic preservation, including the Institute for Criminal Justice Ethics at John Jay College and the Gotham Center for New York City History, founded by Pulitzer Prize-winning historian Mike Wallace.


CUNY United States

Ms Neeti Mitra
University Research Commercialization Manager 

CUNY Institute CoSSMO United States

Our mission is to identify potential projects and participants across CUNY and in the community at large, to help members identify sources of funding and to prepare grant applications, to facilitate the execution of the projects, providing advice, space, and computer facilities, to create research programs by aggregating multiple projects with common defining factors (such programs will promote interactions and networking that will increase the value of the research activities with respect to the contribution of individual projects), to manage program projects with core competencies, and to establish collaborations outside CUNY (national and international)

Professor Felisa Vazquez-Abad
Professor and Executive Director 

CUNY-CITY COLLEGE | the Advanced Vein Visualization, AVV-1 United States

IUSL /Physics Dept. Outcome in Biophotonics Developed at the City University of New York and Lawrence Livermore National Laboratory, the Advanced Vein Visualization, AVV-1 provides a superior illumination and visualization of a patient's veins in both the arm and hand.  The AVV-1 has been designed to help a medical practitioner or nurse to accomplish the task of inserting a needle for an IV or blood draw in a more efficient, timely and safe manner. This will help minimize patient and practitioner stress, treatment delays, and infections from failed attempts. Vein illumination is particularly important when the patient is obese, very young, aged and/or has dark skin. Hopefully, the AVV-1 will soon be on the market at blood test centers and hospitals.

The Advanced Vein Visualization instrument is based on basic research conducted and patented by Robert Alfano and Stavros Demos at the Institute for Ultrafast Spectroscopy and Lasers (IUSL) of The City College of New York (CCNY). Their research was assisted by Michele Alfano-Berwanger

Cushman & Wakefield United States

Cushman & Wakefield is a global leader in commercial real estate services, helping clients transform the way people work, shop, and live. The firm’s 43,000 employees in more than 60 countries provides deep local and global insights that create significant value for occupiers and investors around the world.


agency leasing, global occupier services, asset services, investment management (branded DTZ Investors), capital markets, project & development services, facility services (branded C&W Services), tenant representation and valuation & advisory

Mr Bill Hartman
Executive Vice President 

Cydan: Orphan Drug Accelerator United States

Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.


Orphan Drugs, Rare Diseases, Genetic Disorders

Ms Vered Bisker-Leib
Chief Business Officer